Biomarkers /
RUNX1T1
Overview
RUNX1T1 (Runt-related transcription factor 1; translocated to, 1 (cyclin D-related)), also known as AML1T1, ETO, and MTG8, is a gene that codes for a transcription-regulating protein. The RUNX1-RUNX1T1 fusion has been primarily observed in acute myeloid leukemia.
RUNX1T1 is altered in 2.13% of all cancers with lung adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, melanoma, and cutaneous melanoma having the greatest prevalence of alterations [3].
The most common alterations in RUNX1T1 are RUNX1T1 Amplification (0.89%), RUNX1T1 Fusion (0.10%), RUNX1T1 R31C (0.08%), RUNX1T1 E238K (0.09%), and RUNX1T1 G575R (0.07%) [3].
Clinical Trials
Significance of RUNX1T1 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.